Article
Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial.
The Lancet. Respiratory medicine - 1 Sept 2018
Wang Zhijie, Cheng Ying, An Tongtong, Gao Hongjun, Wang Kai, Zhou Qing, Hu Yanping, Song Yong, Ding Cuimin, Peng Feng, Liang Li, Hu Yi, Huang Cheng, Zhou Caicun, Shi Yuankai, Zhang Li, Ye Xin, Zhang Meizhuo, Chuai Shaokun, Zhu Guanshan, Hu Jin, Wu Yi-Long, Wang Jie
Abstract excerpt
BACKGROUND: Detection of EGFR mutations in tumour tissue is the gold-standard approach to ascertain if a patient will benefit from treatment with an EGFR tyrosine kinase inhibitor. However, if tissue is scant, another strategy is to use circulating tumour DNA (ctDNA), but this method needs validation in clinical trials. We did a prospective clinical trial to assess ctDNA-based EGFR mutation detection as a...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.